Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490283 | 1.00 | MEN1 (0.39) | MEN1KMT2ASIGMAR1HDAC1POLB | |
| SCHEMBL23769067 | 0.84 | HDAC1 (0.34) | HDAC1DRD2DRD3LMNACYP19A1 | |
| SCHEMBL31490092 | 0.84 | HDAC1 (0.34) | HDAC1DRD2DRD3LMNACYP19A1 | |
| SCHEMBL31490134 | 0.82 | DRD2 (0.34) | SIGMAR1HDAC1DRD2DRD3LMNA | |
| SCHEMBL23769078 | 0.82 | DRD2 (0.34) | SIGMAR1HDAC1DRD2DRD3LMNA | |
| SCHEMBL28914142 | 0.81 | KMT2A (0.41) | MEN1KMT2APOLBALDH1A1LMNA | |
| SCHEMBL23769091 | 0.77 | DRD2 (0.40) | SIGMAR1DRD2DRD3LTA4HLMNA | |
| SCHEMBL31490161 | 0.77 | DRD2 (0.40) | SIGMAR1DRD2DRD3LTA4HLMNA | |
| SCHEMBL23769122 | 0.73 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL29978800 | 0.73 | SMN1; SMN2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| CN-115151304-A | Small molecule interferon gene stimulating factor (STING) antagonists | 库拉德夫制药私人有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021161230-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | MEN1 1700/4885KMT2A 4579/4885SIGMAR1 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.